8-K filed May 13, 2024, 7:59 PM ET ticker OKUR CIK 0001637715

M&A confidence high sentiment neutral materiality 0.85

Reneo Pharma to merge with OnKure in reverse merger; OnKure stockholders to own 69.4% of combined company

OnKure Therapeutics, Inc.

OnKure stockholders expected to own ~69.4% of combined entity; Reneo holders ~30.6% on fully-diluted basis.
Concurrent $65M PIPE investment committed from OnKure existing stockholders and new investors.
OnKure valued at $170M, Reneo at $75M; exchange ratios subject to net cash adjustment (±$1M threshold).
Post-merger board: 8 members, 6 designated by OnKure and 2 by Reneo; current Reneo CEO and execs to resign.
Reneo will seek stockholder approval for name change to 'OnKure Therapeutics', reverse stock split, and share issuance.

item 1.01 item 3.02 item 5.01 item 5.02 item 7.01 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Ashley F. Hall

Other Named Officer

OKUR · OnKure Therapeutics, Inc.

Filed: May 13, 2024, 7:59 PM ET

each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.

Departed

Alejandro Dorenbaum

Other Named Officer

OKUR · OnKure Therapeutics, Inc.

Filed: May 13, 2024, 7:59 PM ET

each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.

Departed

Gregory J. Flesher

Other Named Officer

OKUR · OnKure Therapeutics, Inc.

Filed: May 13, 2024, 7:59 PM ET

each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Ashley F. Hall departed as other_named_officer at OnKure Therapeutics, Inc..

Action: resign

Exact text from the filing

each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Alejandro Dorenbaum departed as other_named_officer at OnKure Therapeutics, Inc..

Action: resign

Exact text from the filing

each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Gregory J. Flesher departed as other_named_officer at OnKure Therapeutics, Inc..

Action: resign

Exact text from the filing

each of Mr. Flesher, Mr.Dorenbaum, and Ms. Hall are expected to resign as executive officers of Reneo.

View on SEC.gov

Material Agreements SEC 8-K Item 1.01/1.02 confidence 0.9

OnKure Therapeutics, Inc. entered into Merger Agreement with Reneo Pharmaceuticals, Inc. (effective 2024-05-10).

Action: entry
Agreement: merger
Counterparty: Reneo Pharmaceuticals, Inc.
Effective: 2024-05-10

Exact text from the filing

On May 10, 2024, Reneo Pharmaceuticals, Inc., a Delaware corporation (“ Reneo ”) entered into an Agreement and Plan of Merger (the “ Merger Agreement ”) by and among Reneo, Radiate Merger Sub I, Inc., a Delaware corporation and a direct, wholly owned subsidiary of Reneo (“ Merger Sub I ”), Radiate Merger Sub II, LLC, a Delaware limited liability company and a direct, wholly owned subsidiary of Reneo (“ Merger Sub II ”), and OnKure, Inc., a Delaware corporation (“ OnKure ”)

View on SEC.gov

299 material agreements filed in the last 30 days. Browse all material agreements →

OnKure Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-24-136785

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.